Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.46 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.44 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4476914 | 0.95 | PTGS2 (0.57) | PTGS2PTGS1MEN1KMT2ASLC16A3 | |
| SCHEMBL13239862 | 0.84 | PTGS2 (0.58) | PTGS2PTGS1ALOX5SLC16A3SLC16A1 | |
| SCHEMBL4477596 | 0.82 | PTGS2 (0.57) | PTGS2PTGS1MEN1KMT2ASLC16A3 | |
| SCHEMBL4476916 | 0.81 | PTGS2 (0.46) | PTGS2PTGS1MEN1KMT2AALOX5 | |
| SCHEMBL2917637 | 0.78 | MEN1 (0.46) | PTGS2PTGS1MEN1KMT2AALOX5 | |
| SCHEMBL6411227 | 0.77 | PTGS2 (0.52) | PTGS2PTGS1MEN1KMT2ACA1 | |
| SCHEMBL13637334 | 0.75 | MEN1 (0.52) | PTGS2PTGS1MEN1KMT2AALOX5 | |
| SCHEMBL2910437 | 0.75 | RPA1 (0.70) | MEN1KMT2A | |
| SCHEMBL2920938 | 0.75 | MEN1 (0.43) | PTGS2PTGS1MEN1KMT2AALOX5 | |
| SCHEMBL2911589 | 0.75 | MEN1 (0.43) | PTGS2PTGS1MEN1KMT2AALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | PTGS2 2/4885PTGS1 1/4885MEN1 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.